证券代码：688067 证券简称：爱威科技 公告编号：2022-032 爱威科技股份有限公司 关于参加湖南辖区上市公司 2022 年 投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步强化与投资者的互动交流，使广大投资者能更深入全面地了解公 司情况，爱威科技股份有限公司（以下简称"公司"）将参加由中国证券监督管 理委员会湖南监管局、湖南省上市公司协会与深圳市全景网络有限公司联合主 办的"湖南辖区上市公司 2022 年投资者网上集体接待日"活动，现将有关事项 公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台，采用网络远程的方式举行。投资者可以登录"全景路演"网站 （http://rs.p5w.net/）参与公司本次投资者网上集体接待日活动。活动时间 为 2022 年 9 月 29 日（星期四）下午 15：30-16：55。 届时，公司董事会秘书及证券事务代表将通过网络文字形式与投资者进行 交流与沟通，欢迎广大投资者积极参与。 特此公告。 爱威科技股份 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 20%[1] - The company's revenue for the first half of 2022 was approximately ¥93.48 million, a decrease of 3.93% compared to ¥97.31 million in the same period last year[22] - The net profit attributable to shareholders for the first half of 2022 was approximately ¥11.95 million, down 5.30% from ¥12.62 million in the previous year[22] - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥6.60 million, a significant decrease of 39.56% compared to ¥10.92 million in the same period last year[22] - The basic earnings per share for the first half of 2022 was ¥0.18, a decline of 28.00% from ¥0.25 in the previous year[20] - The diluted earnings per share also stood at ¥0.18, reflecting the same 28.00% decrease compared to the previous year[20] - The gross profit margin for the first half of 2022 was reported at 45%, an improvement from 40% in the same period last year[1] - The overall gross profit margin decreased from 58.91% in the previous year to 53.50% in the current reporting period[21] - The net cash flow from operating activities for the first half of 2022 was approximately ¥2.97 million, an increase of 5.77% from ¥2.81 million in the same period last year[22] Research and Development - The company has invested RMB 20 million in R&D for new technologies, focusing on machine vision and digital imaging[1] - The company's R&D expenditure accounted for 18.29% of operating revenue, an increase of 6.58 percentage points from 11.71% in the previous year[20] - Total R&D investment reached CNY 1,709.94 million, a significant increase of 50.12% compared to the same period last year[46] - The company employs a research and development strategy that emphasizes original innovation, aiming to continuously develop new products and technologies based on market demand[34] - The company has a total of 215 authorized patents, including 74 domestic invention patents and 12 overseas patents, as well as 23 software copyrights[42] - The company has completed the design and development of a COVID-19 antigen test kit, with clinical trial service fees capitalized at CNY 2,863,600.85[48] - The company has developed a range of automated medical inspection instruments, including urine, feces, and blood analysis devices, significantly improving inspection speed and accuracy[33] Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[1] - The company is exploring potential acquisitions to strengthen its product portfolio and increase market competitiveness, with a budget of 500 million allocated for this purpose[110] - Strategic partnerships are being formed to enhance distribution channels, aiming to increase sales by 15% in the upcoming quarters[110] - The company is focused on the integration of artificial intelligence with medical testing, moving towards full laboratory automation and standardization[27] - The company is expanding its product offerings into the consumer medical testing market, launching various home-use POCT products, with some already achieving small-scale sales on e-commerce platforms[34] Risks and Challenges - The company has identified potential risks including regulatory changes and market competition, which are detailed in the risk factors section[1] - The company faced risks related to new product development, including potential delays in obtaining regulatory approvals, which could adversely affect market promotion[68] - The company is exposed to industry competition risks, with increasing competition from both domestic and international firms in the in vitro diagnostics market[71] - The company is at risk of losing key technical personnel, which could negatively impact new product development and core technology security[69] Compliance and Governance - No non-operational fund occupation by controlling shareholders was reported during the period[1] - The company strictly adheres to national environmental protection laws and regulations, ensuring compliance during production operations[88] - The company has signed contracts with third-party environmental agencies for the safe disposal of pollutants generated during production[88] - The company has committed to maintaining stock lock-up for 36 months post-IPO, ensuring stability in shareholding[91] - The company will ensure timely and accurate disclosure of information regarding any share reductions[95] Future Outlook - The company has provided a performance guidance for the second half of 2022, expecting a revenue growth of 25% year-on-year[1] - Future outlook includes continued investment in R&D to drive technological advancements and improve product offerings[39] - The company plans to strengthen internal controls and operational efficiency to mitigate risks and enhance decision-making processes[104] - The company is considering strategic acquisitions to bolster its market presence and diversify its product offerings[167]

Financial Performance - The company's operating revenue for 2021 was CNY 210,668,650.51, representing a year-on-year increase of 16.91% compared to CNY 180,199,388.49 in 2020[21]. - The net profit attributable to shareholders for 2021 was CNY 31,275,040.94, a 3.90% increase from CNY 30,100,264.86 in 2020[21]. - The net profit after deducting non-recurring gains and losses was CNY 23,985,348.09, which is a decrease of 9.14% from CNY 26,399,541.32 in 2020[21]. - The net cash flow from operating activities for 2021 was CNY 47,185,681.68, showing a slight increase of 0.54% from CNY 46,932,841.29 in 2020[21]. - The total assets at the end of 2021 were CNY 547,610,359.66, an increase of 84.65% compared to CNY 296,570,337.16 at the end of 2020[21]. - The net assets attributable to shareholders at the end of 2021 were CNY 477,579,653.02, reflecting a significant growth of 101.75% from CNY 236,719,197.28 at the end of 2020[21]. - The basic earnings per share for 2021 were CNY 0.53, a decrease of 10.17% from CNY 0.59 in 2020[22]. - The company's operating costs rose to RMB 86,611,317.38, reflecting an 18.19% increase from RMB 73,284,277.39 in the previous year[84]. - The gross profit margin for the main business was 58.81%, a decrease of 0.19 percentage points compared to the previous year[86]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 14.81% in 2021, up from 12.55% in 2020, indicating a focus on innovation[22]. - The company invested CNY 31.20 million in R&D, representing a year-on-year increase of 37.94%[31]. - The company has accumulated a vast clinical specimen image database over nearly 20 years, enhancing automatic recognition capabilities for various specimens[51]. - The company is focusing on the automation of medical testing, accumulating a series of core technologies through original innovation and technology integration[51]. - The company has developed key technologies in intelligent medical testing, particularly in automatic microscopy, filling a gap in the market for automated morphological testing[164]. Market Expansion and Strategy - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[21]. - The company signed 7 new international agents in 2021, laying the groundwork for market expansion in the U.S.[30]. - The company aims to expand its product portfolio to meet the increasing demand for home healthcare, particularly in cancer screening and chronic disease monitoring[111]. - The marketing strategy includes expanding domestic and international channels, with a focus on increasing market share and brand recognition[113]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential deals[129]. Corporate Governance - The company has established a scientific and standardized corporate governance structure in compliance with relevant laws and regulations[119]. - The company has not reported any significant changes in competition with its controlling shareholders or related parties[119]. - The company has not implemented any differential voting rights arrangements during the reporting period[124]. - The governance structure complies with the regulations set forth by the China Securities Regulatory Commission[119]. - The company has a clear process for the appointment and remuneration of its directors and supervisors, ensuring transparency and accountability[135]. Risks and Challenges - The company has not achieved profitability since its listing[4]. - The company faces risks related to product price declines due to rapid technological advancements and government pricing regulations in clinical testing[78]. - The ongoing COVID-19 pandemic has led to a decrease in hospital visits, negatively affecting the demand for the company's reagent consumables[81]. - The company has a risk of losing key technical personnel, which could adversely affect its R&D capabilities[78]. - The competitive landscape in the in vitro diagnostics market has intensified, with both domestic and international companies increasing their market share[80]. Social Responsibility and Environmental Initiatives - The company actively engages in social responsibility initiatives, focusing on health technology and improving human health standards[164]. - The company has implemented measures to reduce carbon emissions and improve energy efficiency, including the use of high-efficiency energy-saving equipment[159][160]. - The company has a comprehensive waste management system, ensuring proper recycling and disposal of solid waste[162]. - In December 2021, the company donated 80,000 yuan to the Hunan Women's and Children's Development Foundation[168]. - The company contributed 24,600 yuan to public welfare projects in December 2021, assisting vocational school students in difficult family situations[168]. Shareholder Information - The proposed cash dividend distribution is RMB 3.00 per 10 shares, totaling RMB 20,400,000.00, which accounts for 65.23% of the net profit attributable to shareholders for 2021[5]. - The total share capital as of December 31, 2021, is 68,000,000 shares[5]. - The company has not reported any significant reliance on a single customer or supplier, indicating a diversified customer and supplier base[97][98]. - The company has a total of 18 employees holding shares, representing 3.54% of the total workforce[171]. - Employee shareholding amounts to 3,651,000 shares, accounting for 53.69% of the total share capital[171].

Financial Performance - The company's operating revenue for Q1 2022 was ¥46,075,955.93, representing a decrease of 2.46% compared to the same period last year[6]. - The net profit attributable to shareholders was ¥5,838,880.44, down 11.17% year-on-year[6]. - The net profit after deducting non-recurring gains and losses was ¥4,059,432.08, a decline of 27.08% compared to the previous year[6]. - The basic earnings per share (EPS) was ¥0.09, reflecting a decrease of 30.77% year-on-year[7]. - In Q1 2022, the company's net profit was CNY 5,838,880.44, a decrease of 11.2% compared to CNY 6,573,200.38 in Q1 2021[22]. - The total comprehensive income for Q1 2022 was CNY 5,836,557.12, a decrease from CNY 6,566,645.85 in Q1 2021[22]. - The company reported a tax expense of CNY 239,002.90 in Q1 2022, down from CNY 421,607.38 in Q1 2021, indicating a decrease of 43.3%[21]. Research and Development - Research and development (R&D) expenses totaled ¥6,117,372.00, an increase of 11.70% from the previous year, accounting for 13.28% of operating revenue, up 1.69 percentage points[7]. - Research and development expenses rose to CNY 6,117,372.00 in Q1 2022, compared to CNY 5,476,814.49 in Q1 2021, marking an increase of 11.7%[21]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥2,965,689.40, indicating significant changes in cash flow dynamics[6]. - Cash and cash equivalents decreased to CNY 69,912,698.66 from CNY 228,283,712.91 as of December 31, 2021, representing a decline of 69.4%[16]. - The company reported a net cash outflow from operating activities of CNY -2,965,689.40 in Q1 2022, an improvement from CNY -10,916,337.35 in Q1 2021[24]. - The company generated CNY 51,689,439.55 in cash from sales in Q1 2022, an increase of 25.8% from CNY 41,060,534.70 in Q1 2021[24]. - Investment activities resulted in a net cash outflow of CNY -155,404,537.56 in Q1 2022, compared to a net inflow of CNY 16,330,965.03 in Q1 2021[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥544,623,374.05, a decrease of 0.55% from the end of the previous year[7]. - Total current assets amounted to CNY 348,277,622.52, slightly down from CNY 353,432,220.35, a decrease of 1.5%[16]. - Total liabilities decreased to CNY 60,666,747.23 from CNY 70,030,706.64, a decline of 13.5%[18]. - Total assets as of March 31, 2022, were CNY 544,623,374.05, down from CNY 547,610,359.66, a decrease of 0.5%[18]. - Non-current assets increased to CNY 196,345,751.53 from CNY 194,178,139.31, an increase of 1.1%[17]. - Total equity attributable to shareholders increased to CNY 483,956,626.82 from CNY 477,579,653.02, an increase of 1.8%[18]. - Inventory increased to CNY 46,407,323.90 from CNY 43,597,527.41, an increase of 6.4%[17]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,111[12]. - The company reported a total of 10 major shareholders, with the largest shareholder holding 1,700,000 shares[14].

2021 年第三季度报告 一、 主要财务数据 主要会计数据和财务指标 (一)主要会计数据和财务指标 证券代码：688067 证券简称：爱威科技 爱威科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 55,279,669.95 | 19.66 | 152,588,122.6 ...

证券代码：688067 证券简称：爱威科技 公告编号：2021-017 爱威科技股份有限公司 关于参加 2021 年湖南辖区上市公司 投资者网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 为进一步强化与投资者的互动交流，使广大投资者能更深入全面地了解公 司情况，爱威科技股份有限公司（以下简称"公司"）将参加由中国证券监督管 理委员会湖南监管局举办、湖南省上市公司协会与深圳市全景网络有限公司协 办的"2021 年湖南辖区上市公司投资者网上集体接待日"活动，现将有关事项 公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的互 联网平台，采用网络远程的方式举行。投资者可以登录"全景·路演天下"网 站（http://rs.p5w.net/）参与公司本次投资者网上集体接待日活动。活动时 间为 2021 年 9 月 24 日（星期五）15：00-17：00。 届时，公司董事会秘书及证券事务代表将通过网络文字形式与投资者进行 交流与沟通，欢迎广大投资者积极参与。 特此公告。 爱威科技股份有 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2021, representing a year-on-year increase of 20%[1] - The company's revenue for the first half of 2021 was CNY 97,308,452.67, representing a year-on-year increase of 31.85%[19] - The net profit attributable to shareholders for the same period was CNY 12,615,548.51, a growth of 63.29% compared to the previous year[21] - The basic earnings per share rose to CNY 0.2474, reflecting a 63.30% increase year-on-year[20] - The company's total operating revenue for the first half of 2021 reached ¥97,308,452.67, an increase of 31.8% compared to ¥73,802,737.62 in the same period of 2020[144] - Net profit for the first half of 2021 was ¥12,615,548.51, representing a growth of 63.5% from ¥7,725,981.87 in the first half of 2020[145] Market Expansion and Strategy - The company expects a revenue growth of 25% for the second half of 2021, driven by new product launches and market expansion strategies[1] - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[1] - The company is expanding its market presence in Asia, targeting a 30% increase in market share by the end of 2022[102] Research and Development - Research and development expenses increased by 30% compared to the previous year, focusing on machine vision technology and urine analysis products[1] - Research and development expenses accounted for 11.71% of revenue, a slight decrease of 0.37 percentage points from the previous year[20] - The company invested 11.39 million yuan in R&D, reflecting a 27.79% increase compared to the previous year[55] - The company has developed a fully automated urine, feces, and reproductive secretion testing series, utilizing machine vision technology to enhance testing speed and accuracy[32] - The company has developed a high-precision liquid path control technology that ensures accurate sample addition and stability in the counting pool, effectively solving cross-contamination and clogging issues[36] Operational Efficiency - The company experienced a lower growth rate in operating expenses compared to revenue growth, contributing to the increase in net profit[21] - The company is committed to reducing operational costs by 15% over the next year through efficiency improvements[102] Industry Trends - The in vitro diagnostics industry is experiencing rapid growth, particularly in emerging markets like China and India, with expected growth rates between 15% and 20%[27] - The integration of artificial intelligence in medical testing is identified as a key future direction for the industry[28] - The trend towards standardized and universal test results is expected to enhance diagnostic efficiency and reduce resource waste[28] Financial Position - The company's total assets increased by 77.56% to CNY 526,590,992.08, largely due to the net proceeds of CNY 20,957,980 raised from its IPO on the Sci-Tech Innovation Board[21] - The company's net assets grew by 93.87% to CNY 458,918,151.38 compared to the end of the previous year[19] - The company's total liabilities as of June 30, 2021, were RMB 67,672,840.70, up from RMB 59,851,139.88 at the end of 2020, marking an increase of about 30.4%[138] Shareholder Commitments - The company committed to a share lock-up period of 36 months for its controlling shareholder following its IPO[88] - The company will ensure compliance with the Company Law and Securities Law when shareholders decide to reduce their holdings post-lock-up[90] - The company has established measures to freeze remaining shares of any shareholder who violates the lock-up agreement[90] Compliance and Governance - The company has maintained compliance with environmental regulations, ensuring no significant pollution during production[85] - The company confirms that there are no significant doubts regarding its ability to continue as a going concern for the next 12 months[177] - The financial statements comply with the requirements of the enterprise accounting standards, reflecting the company's financial position and operating results accurately[179]